The QualityStocks Daily Wednesday, June 15th, 2022

Today's Top 3 Investment Newsletters

The Online Investor(AUST) $2.2300 +27.44%

QualityStocks(FCUV) $13.9000 +25.68%

MarketBeat(UP) $2.3500 +22.40%

The QualityStocks Daily Stock List

HIVE Blockchain Technologies Ltd. (HIVE)

InvestorPlace, MarketClub Analysis, MarketBeat, QualityStocks, StreetInsider, StockMarketWatch, Marketbeat.com, Greenbackers, Hit and Run Candle Sticks, Barchart, Stock Market Watch, WealthMakers, StockOodles, StreetAuthority Daily, TopStockAnalysts, Wall Street Resources and smartOTC reported earlier on HIVE Blockchain Technologies Ltd. (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In what could be a first, crypto-based evidence may be used to prove in court that Russia engaged in acts that can be described as war crimes. Starling Lab, a research facility linked to Stanford University, is spearheading the collection and verification of evidence to support this effort. That evidence has been found on the internet.

For example, there is a photo that was uploaded by someone on Telegram. The photo showed a school building in the Ukrainian city of Kharkiv with a blast hole in one wall, and the user claimed that a missile fired by Russia was responsible for that damage. If this claim is true, it can be used to prove that Russia violated international law by deliberately targeting an educational institution.

The team at Starling Lab isn’t just focusing on any alleged evidence found on the internet. Instead, they have focused on the possible violations Russia committed in the first two weeks of March, and that photo falls within that timeframe. This evidence is collected and then verified using many technologies, including geolocation and collaborating evidence from other sources, such as Human Rights Watch; In addition, the lab also works to verity that investigative stories done by reputable media houses like the CNN.

All these “threads” are linked together using blockchain technology, the technology behind cryptocurrencies such as Bitcoin. The purpose of this verification trail is to ensure that the evidence can stand the rigorous scrutiny of court, and that it is protected from tampering by elements that may be interested in altering the narrative surrounding these different incidents. The blockchain tech also helps preserve vital evidence in case a website pulls down a story or a Twitter user deletes a tweet or account.

Starling Lab and the other entities it is working with are hopeful that the International Criminal Court (ICC) will use the dossier they have submitted detailing at least five attacks that meet the criteria of possible war crimes against Russia. The team believes that its work is bringing to life the objective stated by the ICC in its strategic plan spanning 2016–18 indicating that the court was looking to work with nongovernment actors in the use of technology to gather evidence useful to the court.

If prosecutors are to use the evidence submitted by Starling Lab, they will need to sort it in terms of relevance to specific cases or individuals who have surrendered to the court. They will also need to prove other aspects of the cases, such as the intent of the alleged perpetuators of the attacks against schools.

One thing that can’t be ignored in this effort is the increasing role that social media as well as blockchain technology may have in the way cases are prosecuted in the future. Blockchain and entities such as HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) are showing that there is no limit as to how this technology can be put to use around the world.

HIVE Blockchain Technologies Ltd. (HIVE), closed Wednesday's trading session at $3.1, up 2.649%, on 3,509,096 volume. The average volume for the last 3 months is 51,503 and the stock's 52-week low/high is $2.8201/$28.00.

Alliance Resource Partners LP (ARLP)

The Online Investor, Zacks, TradersPro, MarketBeat, The Street, Marketbeat.com, InvestorPlace, Dividend Opportunities, TopStockAnalysts, TheStockAdvisor, QualityStocks, The Wealth Report, The Motley Fool, Money Morning, StreetAuthority Daily, MarketClub Analysis, Market Intelligence Center Alert, BUYINS.NET, Investing Daily, Daily Wealth, Daily Trade Alert, Rick Saddler, Wealth Insider Alert, The Growth Stock Wire, Trading Concepts, TheOptionSpecialist, TheStockAdvisors, SmarTrend Newsletters, TraderPower, Top Pros' Top Picks, Daily Markets, Trades Of The Day, Eagle Financial Publications, FNNO Newsletters, Greenbackers, Insider Wealth Alert, Short Term Wealth, Investor Update, Leeb's Market Forecast, TheTradingReport, TheStreet Offers, Money and Markets, PoliticsAndMyPortfolio.com, StreetInsider and Investment U reported earlier on Alliance Resource Partners LP (ARLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Currently, coal provides more than 35% of the world’s electricity. It was largely responsible for the Industrial revolution and allowed us to generate electricity and mass-produce commodities; In addition, it provided fuel for transport. However, coal is also responsible for a significant percentage of global greenhouse gas emissions. Burning coal produces more than 700 million metric tons of carbon dioxide every year in the United States alone. Using coal as an energy source is also associated with environmental impacts such as acid rain, smog, ground-level ozone and particulate emissions.

Speaking at the Bonn Climate Conference, U.S. Envoy on climate change John Kerry said the world is “cooked” if it continues using coal in response to the Russia-Ukraine war. Kerry criticized several countries during an interview with the BBC for failing to keep the promises they made during the 2021 United Nations Climate Change Conference.

As countries continue to deal with the reverberating effects of Russia’s invasion of Ukraine across the energy sector coupled with a rise in the cost of living, the unity they displayed last year in Glasgow will be put to the test.

Despite all these geopolitical factors, Kerry said, the world still isn’t moving speedily enough to arrest the carbon emissions that are driving runaway climate change. He added that while reducing global carbon emissions is a battle we can win, it will require a “wholesale elevation of effort” by countries around the world.

Ukrainian scientist Dr. Svitana Krakovska also encouraged the delegates to hasten the transition from fossil fuels to green energy, stating that oil and gas were the “enablers of war.”

The delegates may not be able to achieve much, however, as they are mostly civil servants with little political input. Furthermore, an analysis by BBC shows that member states haven’t done a lot to remedy the issues discussed in the Glasgow Climate Pact. This is partly because the November conference was swiftly followed by a sharp increase in gas prices that triggered an energy crisis. In addition, the coronavirus pandemic and subsequent lockdowns messed up the global supply chain while the Russia-Ukraine war only compounded the energy crisis. Countries such as Egypt, which hosted COP27, and India have been slow to submit their new carbon-cutting strategies.

Alex Scott from environmental think tank E3G said the ongoing Bonn talks would be the real test to see whether countries would stand by their word and genuinely commit to making the policy changes needed to significantly decrease carbon emissions.

As those carbon reduction commitments are gradually implemented, coal mining companies such as Alliance Resource Partners LP (NASDAQ: ARLP) will continue helping bridge the energy supply gaps that have resulted in significant spikes in the prices of different forms of energy.

Alliance Resource Partners LP (ARLP), closed Wednesday's trading session at $18.17, up 1.5651%, on 336,901 volume. The average volume for the last 3 months is 489,354 and the stock's 52-week low/high is $6.62/$21.24.

Cerberus Cyber Sentinel Corp. (CISO)

We reported earlier on Cerberus Cyber Sentinel Corp. (CISO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cerberus Cyber Sentinel (NASDAQ: CISO), a managed compliance and cybersecurity provider based in Scottsdale, Arizona, will be joining the broad-market Russell 2000(R) Index. The company announced the decision, noting that it will be joining the index at the conclusion of the 2022 Russell indexes annual reconstitution and effective after the U.S. market opens on June 27, 2022. According to the announcement, the annual Russell indexes reconstitution includes the 4,000 largest U.S. stocks as of May 6, 2022, listing them based on total market capitalization. Investment managers and institutional investors often refer to the Russell indexes for index funds and as benchmarks for active investment strategies. The announcement noted that an estimated $12 trillion in assets are benchmarked against Russell’s U.S. indexes, which are part of FTSE Russell, a leading global index provider. “It is a tremendous honor to be included in the Russell 2000," said Cerberus Sentinel founder and CEO David Jemmett in the press release. “Following our uplisting to the Nasdaq Capital Market on Jan. 14, 2022, this is further validation of the company's strengths to us and our stockholders.”

To view the full press release, visit https://ibn.fm/K3zaz

About Cerberus Cyber Sentinel Corp.

Cerberus Sentinel is an industry leader in managed cybersecurity and compliance (“MCCP”) services with its exclusive MCCP+ managed compliance and cybersecurity services plus culture program. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CerberUSSentinel.com.

Cerberus Cyber Sentinel Corp. (CISO), closed Wednesday's trading session at $5.41, up 4.0385%, on 606,742 volume. The average volume for the last 3 months is 1.346M and the stock's 52-week low/high is $2.61/$49.00.

EQRx Inc. (EQRX)

MarketBeat and QualityStocks reported earlier on EQRx Inc. (EQRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

EQRx Inc. (NASDAQ: EQRX) is a pharmaceutical firm that is focused on the development of medicines for the treatment of immune-inflammatory and oncology diseases.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2021, on January 25th. The firm serves consumers around the globe.

The company is focused on re-engineering the process from drug discovery to patient delivery, with the objective of providing a market-based solution for the growing cost of drugs. It seeks to discover, develop and deliver patent-protected and high quality medicines in a more efficient and cost-effective way through the use of the latest advancements in science and technology.

The enterprise’s pipeline consists of its pre-registrational programs like an anti-programmed death-ligand 1 antibody dubbed Sugemalimab, which has been developed to treat stage 3 and 4 non-small cell lung cancer; and an epidermal growth factor receptor inhibitor dubbed Aumolertinib, which has been developed to treat patients with epidermal growth factor receptor-mutated non-small cell lung cancer. Other programs in the pipeline include pre-clinical and clinical stage assets, like an anti-programmed death-1 antibody known as EQ176, which is undergoing phase 3 trials evaluating its effectiveness in treating primary liver cancer. It also develops a small molecule cyclin-dependent kinase 4/6 inhibitor dubbed Lerociclib, which is undergoing phase 1 clinical trials testing its efficacy in treating metastatic breast cancer; and a selective janus kinase-1 inhibitor dubbed EQ121, which is in a number of phase 1 trials for various indications.

The firm is focused on advancing its Sugemalimab formulation after it demonstrated significant improvement in overall survival when used in combination with chemotherapy. It plans to acquire approval for the formulation, with its objective being to deliver a low-cost treatment option to patients, which will not only benefit the patients but also boost the firm’s growth.

EQRx Inc. (EQRX), closed Wednesday's trading session at $4.39, up 15.5263%, on 3,278,652 volume. The average volume for the last 3 months is 582,846 and the stock's 52-week low/high is $2.63/$8.6999.

Focus Universal, Inc. (FCUV)

QualityStocks and The Street reported earlier on Focus Universal, Inc. (FCUV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Focus Universal, Inc. is a universal smart instrumentation platform developer and universal smart device manufacturer in the IOT (Internet of Things) market. The Focus Universal technology features a Universal Smart Instrumentation Platform (USIP). The USIP provides an inventive and universal solution for embedded design, industrial control and monitoring. Focus Universal is based in Walnut, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Regarding Focus Universal’s services, the Company offers Large Scale Custom Installation. It can map out any commercial installation requirements and customize a package of devices and sensors to fit any needs.

The above-mentioned USIP uses a mobile device or computer to communicate with smart devices to monitor and control any functions. Consequently, it replaces traditional instrument hardware. The features of the Focus Universal USIP include Universal Customization; Cost Saving; Interoperability; Security; Ease of Use; Scalability; Cloud Instrumentation; and Fast Prototyping.

The smart app interface supports real-time data monitoring. It facilitates instrument control and operation. A wireless data logger (Ubiquitor) acts as a link between the smart device and sensor data acquisition module. The Universal Smart Controller (USC) permits a user to control any device by plugging the sensors into the platform using their smartphone.

Focus Universal previously announced that it appointed Mr. Greg Butterfield as an independent Board Member to the Focus Universal team. Mr. Butterfield is a proven entrepreneur in the technology sector and active member in the technology community. He is the Founder and Managing Partner of SageCreek Partners ('SCP') a technology commercialization and consulting firm.

Desheng Wang, Focus Universal Chief Executive Officer, said, ''Mr. Butterfield has a fantastic background in the technology sector that we believe can add great value to our board. He brings expertise in M&A and management experience with both private and public companies that will be a great addition moving forward.''

Focus Universal, Inc. (FCUV), closed Wednesday's trading session at $13.9, up 25.6781%, on 214,295 volume. The average volume for the last 3 months is 5.324M and the stock's 52-week low/high is $4.49/$25.25.

Charge Enterprises (CRGE)

QualityStocks, Wall Street Grand, 24-7 Stock Alert, Whitehotstocks, Stockhunter.us, Penny Stock Explosion, Open Water Investments, Super Stock Investor, Street Insider, MicroStockProfit, Real Pennies, Stock Preacher, HotOTC, Green Energy Stocks, Global Equity Report, Dubai Penny Stocks, CoolPennyStocks, AnotherWinningTrade, Beacon Equity Research, Topgun stockpicks, Stock Rich, InvestorPlace, Monster Stock Alerts, Bull in Advantage, BullRally, Lebed.biz, Gold and Energy Advisor, Investor Ideas, Investment House, Free Hot Penny Stocks, Market FN, Stock Research Newsletter, Whisper from Wall Street, Traders Content, Trader Central, Top Secret Stocks, TooNiceStocks, The Stock Psycho, The Best Newsletters, Stockpalooza, PROFIT CONFIDENTIAL, StockEgg, OTCReporter, Stock Marketing Inc., SmallCapNetwork, Sling-Shot-Stocks, SeriousTraders, Richard Atlas, PubCo Journal, Penny PayDay, Penny Invest and stockmarketinginc reported earlier on Charge Enterprises (CRGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Charge Enterprises Inc. (NASDAQ: CRGE) is engaged in the provision of solutions in the electric vehicle charging and wireless network infrastructure installation, including small cell, distributed antennae systems, tower, 5G and electrical infrastructure.

The firm has its headquarters in New York, the United States and was incorporated in 2003, on May 8th. Prior to its name change in January 2021, the firm was known as TransWorld Holdings Inc. It operates as part of the technology sector. The firm serves consumers in the United States.

The company is focused on connecting individuals everywhere using a strategy in telecom network infrastructure, electric vehicle charging infrastructure installation and maintenance and connected calls. It operates through the Infrastructure and the Telecommunications segments. The Infrastructure segment is focused on physical wireless networking elements, including in-building applications, small cell, cell tower, 5G and 4G and EVC solutions. This includes the designing, engineering, construction, installation and maintenance of electric vehicle chargers. This segment also provides a network of personal charging power banks in sporting arenas, transit hubs, restaurants and bars. On the other hand, the Telecommunications segment provides time-division multiplexing access and internet-protocol-based access for domestic switching and associated peripheral equipment services; and long-distance data and voice minutes. It also offers carrier-grade switches and routers for circuit-based and internet services, as well as connection of data and voice call services.

The enterprise was recently approved for uplisting to the Nasdaq Global Market. This approval opens up the enterprise to growth opportunities as well as numerous investments, which will bolster its growth significantly.

Charge Enterprises (CRGE), closed Wednesday's trading session at $5.07, up 21.2919%, on 3,386,885 volume. The average volume for the last 3 months is 34.384M and the stock's 52-week low/high is $2.51/$8.46.

UserTesting Inc. (USER)

MarketBeat reported earlier on UserTesting Inc. (USER), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

UserTesting Inc. (NYSE: USER) operates an SaaS platform (Software-as-a-service) which allows organizations to find out more about experiences of the individuals they engage with processes, applications, designs, products, brands or concepts.

The firm has its headquarters in San Francisco, California and was incorporated in June 2007 by David Garr and Darrell Benatar. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe, with a focus on consumers in the United Kingdom and the United States.

The company provides usability testing and research tools which capture highly contextualized, credible and authentic customer perspectives from targeted audiences to improve consumer experiences online.

The enterprise develops a UX platform (user experience platform). This platform captures perspectives from targeted audiences sharing their thoughts for omnichannel, real-world or digital experiences. It sells its solutions through field sales representatives and a direct selling motion. It also has a sales organization that sells to small and medium sized as well as mid-market business customers. The enterprise serves consumers in the manufacturing, food and beverage, transportation, healthcare, education, gaming, public, media entertainment, hospitality and travel, professional service, automotive, consumer products, e-commerce and retail, B2B and B2C technology, and financial service industries.

The firm recently announced its latest financial results, which show significant increases in its revenues. It is focused on meeting the evolving needs of its consumers and entering into new growth opportunities, which will help create value for its shareholders and bring in more investments into the firm.

UserTesting Inc. (USER), closed Wednesday's trading session at $5.59, up 11.3546%, on 1,142,726 volume. The average volume for the last 3 months is 20.265M and the stock's 52-week low/high is $4.14/$15.98.

Stitch Fix Inc. (SFIX)

Schaeffer's, InvestorPlace, StocksEarning, Cabot Wealth, MarketBeat, The Street, MarketClub Analysis, StreetInsider, Kiplinger Today, The Online Investor, Trades Of The Day, Zacks, Wealth Insider Alert, Daily Trade Alert, Trading Concepts, StockEarnings, Market Intelligence Center Alert, InvestmentHouse, BUYINS.NET, CNBC Breaking News, Investopedia, Stock Up Featured, Top Pros' Top Picks, StockMarketWatch, The Stock Dork, Barchart, Early Bird, StreetAuthority Daily, TradersPro, Rick Saddler, INO Market Report, Market Intelligence Center, Money Morning, QualityStocks and MT4FXTraders reported earlier on Stitch Fix Inc. (SFIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Stitch Fix Inc. (NASDAQ: SFIX) (FRA: SYJ) (LON: 0L9X) is an online personal styling platform that is involved in the sale of a range of accessories, apparel and shoes through its mobile application as well as its website.

The firm has its headquarters in San Francisco, California and was incorporated in February 2011 by Erin Morrison Flynn and Katrina Lake. Prior to its name change in October 2011, the firm was known as Rack Habit Inc. It operates as part of the apparel retail industry, under the consumer cyclical sector. The firm has four companies in its corporate family and serves consumers in the United States.

The company’s mission is to change the way individuals find clothes they love by combining technology with the personal touch of style experts. In addition to helping its clients look great, it helps them save time and enables them to evolve their personal style.

The enterprise provides blouses, dresses, denim, shoes, skirts, handbags and jewelry for kids, women and men under the Stitch Fix brand. It also offers a shipment service dubbed A FIX, which involves stylists picking out a number of items from merchandisers with analysis of merchandise and client data to offer a personalized shipment of accessories, shoes and apparel suited to a client’s needs. The enterprise also sells merchandise across various price points.

The company recently announced its latest financial results, with its CEO noting that they remained focused on positioning the company for value creation and profitable growth over time. This will not only bring in additional revenues and investments into the company but also benefit the company’s shareholders.

Stitch Fix Inc. (SFIX), closed Wednesday's trading session at $6.81, up 9.4855%, on 5,314,434 volume. The average volume for the last 3 months is 7.509M and the stock's 52-week low/high is $5.8502/$64.4999.

Lifeway Foods (LWAY)

TaglichBrothers, InvestorPlace, TradersPro, SmarTrend Newsletters, StreetInsider, StockMarketWatch, Zacks, Stockhouse, Marketbeat.com, Barchart, BUYINS.NET, MarketBeat, National Inflation Association, QualityStocks, 24/7 Trader, SmallCapInvestor.com, Street Insider, The Online Investor, The Street and SmallCap Network reported earlier on Lifeway Foods (LWAY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lifeway Foods, Inc. (NASDAQ: LWAY) (FRA: LWF) is focused on the production and marketing of probiotic-based products.

The firm has its headquarters in Morton Grove, Illinois and was incorporated in February 1986 by Ludmila Smolyansky and Michael Smolyansky. It operates as part of the packaged foods industry, under the consumer defensive sector. The firm serves consumers in the United States, with a focus on those in the state of Illinois.

The company’s mission is to offer the best in nutritious and probiotic foods, in an effort to improve the health of its consumers. It is committed to producing the highest quality of cultured foods while cementing its position in the market as a leader in probiotic drinkables.

The enterprise’s products include a cultured dairy product known as drinkable kefir, which comes in a number of non-organic and organic sizes, flavors and types including protein, whole milk, non-fat, low fat and BioKefir. It also provides European-style creams and soft cheeses; frozen kefir in pint-size and soft serve containers; cupped kefir; and a line of strained kefir and yogurt products dubbed Icelandic Skyr. This is in addition to offering a line of kefir products designed for children known as ProBugs. The enterprise sells its products under private labels as well as under the Fresh Made and Lifeway brand names.

The firm recently appointed new members to its board, and they bring extensive industry experience to the firm. This move supports the firm’s mission to grow sustainably and profitably and will also assist in the creation of long-term value for its shareholders.

Lifeway Foods (LWAY), closed Wednesday's trading session at $4.75, up 4.1667%, on 17,696 volume. The average volume for the last 3 months is 488,612 and the stock's 52-week low/high is $4.55/$9.00.

Gulf Island Fabrication (GIFI)

SmarTrend Newsletters, StreetInsider, MarketBeat, QualityStocks, StreetAuthority Daily, TraderPower, The Street, Top Pros' Top Picks, Zacks, BUYINS.NET, Marketbeat.com, TradersPro, InvestorPlace, Gold and Energy Advisor, CRWEFinance and Short Term Wealth reported earlier on Gulf Island Fabrication (GIFI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gulf Island Fabrication Inc. (NASDAQ: GIFI) is a fabricator of complex steel modules and structures and marine vessels.

The firm has its headquarters in Houston, Texas and was incorporated in 1947 by Alden J. Laborde. It operates as part of the metal fabrication industry, under the industrials sector. The firm serves consumers in the United States.

The company operates through the Corporate, Fabrication and services and the Shipyard segments. The corporate segment represents expenses that aren’t directly related to the operating segment. The fabrication segment is involved in the fabrication of complex steel structures for offshore wind developments and offshore production as well as onshore industrial, LNG, petrochemical and refining facilities. This is in addition to engaging in the provision of maintenance and other services in offshore platforms and onshore facilities as well as performing civil and municipal works projects. On the other hand, the shipyard segment is focused on designing, constructing and repairing of marine vessels. It is also involved in the fabrication of new build marine vessels, which include lift boats, anchor handling vessels, drydocks and barges, towboats, salvage vessels, tugboats, research vessel, MPSVs and OSVs. This is in addition to offering repair and maintenance services. The company serves construction, procurement and engineering firms; power, industrial, LNG, petrochemical and refining operators; and global energy producers.

The enterprise recently released its latest financial results, which show an increase in its revenues. It remains focused on accelerating its business momentum and is well-positioned for continued growth, which will positively influence its investments and consumer reach.

Gulf Island Fabrication (GIFI), closed Wednesday's trading session at $3.25, off by 0.611621%, on 14,920 volume. The average volume for the last 3 months is 435,861 and the stock's 52-week low/high is $3.24/$4.92.

Greenlane Holdings (GNLN)

Schaeffer's, MarketBeat, StockMarketWatch, TradersPro, StreetInsider, The Street, Trades Of The Day, InvestorPlace, Daily Trade Alert and BUYINS.NET reported earlier on Greenlane Holdings (GNLN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Greenlane Holdings Inc. (NASDAQ: GNLN) (FRA: G67) is a holding firm that is focused on the development and distribution of cannabis accessories, vape solutions, child-resistant packaging and lifestyle products.

The firm has its headquarters in Boca Raton, Florida and was incorporated in 2005 by Adam Schoenfeld and Aaron LoCascio. It operates as part of the tobacco industry, under the consumer defensive sector. The firm has fifteen companies in its corporate family and serves consumers in Canada and the United States.

The company operates through the Industrial goods and Consumer goods segments. The industrial goods segment is focused on serving retailers, operators and brands through its wholesale operations by offering essential ancillary products like customizable vaporization and packaging solutions, which include its brand Pollen Gear. On the other hand, the consumer goods segment is focused on serving consumers across e-commerce, retail and wholesale operations through the Higher Standards, Keith Haring, Marley Natural, Vibes, DaVinci and Eyce brands. This is in addition to providing lifestyle accessories and products from the Grenco Science, Bickel, Storz and PAX brands.

The enterprise offers consumption accessories, rolling papers, pipes, vaporizers and grinders as well as rigs, bubblers and other vaporization and smoking-related merchandise and accessories. It serves consumers via a network of more than 8,000 specialty retailers, marijuana dispensaries and smoke shops.

The company recently entered into an agreement with Universal Distribution LLC, which will involve the distribution of its products in Latin America. This move will not only help extend the company’s consumer reach but also bring in additional revenues into the company while bolstering its growth.

Greenlane Holdings (GNLN), closed Wednesday's trading session at $0.25, off by 1.9992%, on 1,117,410 volume. The average volume for the last 3 months is 126,857 and the stock's 52-week low/high is $0.247201/$5.4899.

Cingulate Inc. (CING)

QualityStocks and MarketBeat reported earlier on Cingulate Inc. (CING), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical firm that is engaged in developing, manufacturing and commercializing treatments for neurobiological and central nervous system disorders.

The firm has its headquarters in Morristown, New Jersey and was incorporated in 2013 by Matthew N. Brams, Raul R. Silva, Craig Steven and Shane J. Schaffer. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers in the United States.

The company develops next-generation pharmaceuticals which have been designed to improve the lives of patients suffering from conditions which are characterized by suboptimal treatment outcomes and taxing daily dosing regimens.

The enterprise uses its proprietary precision time-release drug delivery platform technology to develop its pipeline of pharmaceutical products. Its product candidates include dexmethylphenidate (CTx-1301) and dextroamphetamine (CTx-1302), which have been developed to treat ADHD (attention deficit/hyperactivity disorder). These two candidates both contain 3 releases of active pharmaceutical ingredient, combined into a small tablet dosage form. The candidates have been developed for the following core patient segments: adults (aged 18 and above), adolescents (aged 13-17) and children (ages 6-12). In addition to this, the enterprise also develops CTx-2103 for the treatment of anxiety disorders.

The company recently launched an IPO whose proceeds it intends to use for the research, development and pre-commercialization of its ADHD products and for a proof of concept study for its anxiety disorder treatment. The success and approval of these products will bring in more revenues as well as investors into the company, which will be good for its growth.

Cingulate Inc. (CING), closed Wednesday's trading session at $1.4, up 14.7447%, on 120,886 volume. The average volume for the last 3 months is 1.094M and the stock's 52-week low/high is $1.04/$5.15.

The QualityStocks Company Corner

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

  • iGaming customer acquisition costs rising, reducing operator profitability
  • GMGI offers AI-powered iGaming software that provides partners with customer data that boosts monetization strategies, increases player retention
  • System generates skill and game-preference data that enables operators to offer incentives that prolong activity and increase returns

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, leverages the power of AI to maximize profits for its growing B2B customer base.

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.

Technology

Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Wednesday's trading session at $2.24, up 0.44843%, on 20,100 volume. The average volume for the last 3 months is 21,984 and the stock's 52-week low/high is $1.85/$12.50.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertension
  • The company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filing
  • The pre-IND meeting will confirm the details of the company’s IND-enabling program
  • Lexaria also announced it had licensed its DehydraTECH technology to AnodGen, with the announcement following similar out-licensing agreements with Valcon Medical and Premier Science

Early last September, global innovator Lexaria Bioscience (NASDAQ: LEXX) was pleased to announce it had formally commenced the process toward an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”) with its DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension (https://cnw.fm/rDcfI).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $2.24, up 0.44843%, on 20,100 volume. The average volume for the last 3 months is 21,984 and the stock's 52-week low/high is $1.85/$12.50.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced that it will be added as a member of the Russell 3000(R) index at the conclusion of the 2022 Russell indexes annual reconstitution. This is effective after the U.S. market opens on June 27, 2022, according to a preliminary list of additions posted on June 3, 2022. “Cepton is excited to be joining the Russell 3000(R) index as it enables us to expand awareness of our story among the investment community as we continue to execute against our milestones generating long-term stakeholder value,” said Jun Pei, Cepton’s co-founder and CEO. “At Cepton, our design philosophy and technology enabled us to win the largest ADAS series production award to date, and inclusion in the Russell indexes is another point of validation in our ongoing journey as a public company.” To view the full press release, visit https://ibn.fm/0p5dj

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Wednesday's trading session at $1.45, up 0.694444%, on 6,044,992 volume. The average volume for the last 3 months is 6.821M and the stock's 52-week low/high is $1.01/$80.16.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

One thing most consumers can agree on is that electric vehicles are currently too expensive. A small percentage of the population can afford to buy an EV outright, and the industry has depended on government subsidies a great deal to get by. Costly electric vehicle batteries are largely to blame for this. Electric vehicles run on rechargeable lithium-ion battery packs, which are made using a variety of rare and expensive metals such as lithium, nickel, manganese, cobalt and graphite. However, we may soon see cheaper electric vehicles enter the market as the cost of manufacturing them reduces thanks to decreasing lithium costs, says market analyst Credit Suisse. At the moment, raw lithium ore goes for a whopping $8,300 a ton. Head of energy resources research at Credit Suisse Saul Kavonic says lithium is experiencing unprecedented scarcity and prices have “gone through the roof.” As such, he says, the company should be able to sell into a “fairly positive price environment” and generate healthy margins. As lithium extractors experience healthy margins on their operations, so will manufacturers of electric vehicles such as Mullen Automotive Inc. (NASDAQ: MULN).

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $1.16, up 8.4112%, on 40,694,398 volume. The average volume for the last 3 months is 53,194 and the stock's 52-week low/high is $0.52/$15.90.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

America’s cannabis industry exists in a sort of limbo. Although dozens of states now allow the cultivation and sale of cannabis to adults aged 21 and older, federal law still outlaws the plant and considers it a Schedule I controlled drug. This means that even though licensed cannabis businesses are seen as legal commercial enterprises by many states, they cannot access many of the services other industries enjoy. One such service is benefits and grants from the federal government. Cannabis businesses felt this most acutely during the coronavirus pandemic when the national government deployed aid funds to businesses through the federal Small Business Administration (SBA) loans program, but federal law prevented the cannabis companies from accessing much-needed funds. If access to this funding is granted, the sector would grow more steadily and more companies as well as individuals may be interested in giving advanced cultivation equipment such as the grow containers made by Advanced Container Technologies Inc. (OTC: ACTX) and similar companies a try.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Wednesday's trading session at $0.95, up 7.9545%, on 1,118 volume. The average volume for the last 3 months is 7,000 and the stock's 52-week low/high is $0.54/$3.575.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Thailand has become the first country in Asia to decriminalize the cultivation and sale of marijuana. However, Thai residents won’t be living in a recreational cannabis paradise anytime soon. The Asian country plans on enacting strict cannabis policies and tough penalties for anyone caught indulging in recreational weed. According to Thai Health Minister Anutin Charnvirakul, the move is meant to boost Thailand’s economy by tapping into the billion-dollar medical cannabis industry. Anutin cautions against using cannabis recreationally as the country still has laws that control the consumption of marijuana products in a “nonproductive” way. Rather than launch a recreational market, Thailand’s new cannabis laws will allow citizens to grow and sell cannabis and hemp products. As the strict marijuana laws around the region begin to loosen, an opportunity may be created for established cannabis companies such as Flora Growth Corp. (NASDAQ: FLGC) to expand into these emerging markets.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday's trading session at $0.7, up 0.733919%, on 307,638 volume. The average volume for the last 3 months is 28.269M and the stock's 52-week low/high is $0.65/$21.45.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to progressing Psychedelics to Therapeutics(TM), has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. “The company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance,” a recent article reads. “The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset facilitates this; the system is equipped with hi-tech sensors that record brain activity and report a participant’s experience using structured questionnaires and validated assessments during study visits and at follow-up… [Cybin] is collaborating with a network of world-class partners and internationally recognized scientists as it progresses on its mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.” To view the full article, visit https://ibn.fm/B9Ztw. Everyone has experienced it at least once in their lives: you walk into a room with purpose only to realize you have no idea what you came for. You stare at the room, racking your brain for information, but all you draw is a blank. This state of temporary amnesia is the concept behind ego death. Also referred to as ego dissolution, this term has been used in mystic and psychedelic communities for decades to describe a state of temporary autobiographical amnesia. Think of that moment of brain fog stretching over time, leaving you floating in a cloud of nothingness as you swim in a state of temporary amnesia. You have no idea who you are, where you come from or why you even exist. This is ego death, a psychological condition where a fully conscious individual temporarily “forgets” everything about themselves. Those who have experienced it say it felt like all the weight of the biographical selves had been lifted off their bodies, leaving them feeling “light and pleasant.” There are still huge gaps that exist in our understanding of psychedelics and how they work, and the clinical development programs being undertaken by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) will hopefully shed more light on why these substances impact mental health in such diverse ways from traditional treatments.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $0.63, up 10.8569%, on 666,865 volume. The average volume for the last 3 months is 505,919 and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Data shows that at least 700,000 Americans are currently living with brain tumors. However, experts say the average person has less than a 1% chance of developing brain cancer or spinal cord tumor, with the main risk factors being radiation exposure, family history, seizures, and exposure to viruses, allergens and infections. Knowing the warning signs of brain cancer will allow you to obtain the treatment you need as soon as possible and increase your chances of surviving the disease. Below are some symptoms to watch for. Brain tumors can be extremely difficult to cure completely, but they can be managed with timely and adequate care. Visit your physician for a checkup if you suspect you have a brain tumor. The available treatments are being improved as more is known about the different brain cancers, and companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are looking to come up with breakthrough treatments so that more patients can be treated successfully.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.2727, up 2.1348%, on 295,799 volume. The average volume for the last 3 months is 93,766 and the stock's 52-week low/high is $0.2453/$2.68.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is devoted to finding solutions for mental ailments — not simply by easing symptoms, but by attacking the root causes of the difficulties, utilizing a toolbox of innovative, therapeutic substances. “Recently, Delic announced that six of its clinic locations will launch a specialized therapy that has the potential to boost natural energy stores and immunity, brain and DNA function, and cell communication. The NAD+ (nicotinamide adenine dinucleotide) infusion therapy is administered intravenously or intramuscularly and has previously shown evidence that such treatments support the creation of new cells, neuropathways and networks in the brain, which in turn helps patients recover from various mental health conditions… Those conditions include post-traumatic stress disorder (‘PTSD’), suicidality and chronic pain,” explains a recent article. “At KWC (Delic’s Ketamine Wellness Centers), we are committed to building on our holistic approach to mental health wellness and pursuing the most effective and suitable treatments to address our patients’ needs,” KWC CEO and Delic COO Kevin Nicholson stated. To view the full article, visit https://ibn.fm/jriI6

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Wednesday's trading session at $0.0424, up 17.4515%, on 29,107 volume. The average volume for the last 3 months is 97,765 and the stock's 52-week low/high is $0.0309/$0.315.

Recent News

Nowigence Inc. (OTCQB: NOWG)

The QualityStocks Daily Newsletter would like to spotlight Nowigence Inc. (OTCQB: NOWG).

Nowigence (OTCQB: NOWG) is the software-as-a-service (“SaaS”) technology firm behind Pluaris(TM), a comprehensive and turnkey AI knowledge engine. The company announced yesterday that its common stock commenced trading on the OTCQB Venture Market, the mid-tier OTC equity market, which lists primarily early-stage and developing companies in the U.S. and international markets. “Today, we celebrate a historic milestone in our growth journey that began five years ago. We have now emerged from a private company to a publicly traded company. Pluaris allows all of us to learn more in less time solving the information overload problem we all are experiencing at work and at home. This machine learning and natural language processing app mimics the way we absorb knowledge as humans while searching through massive volumes of information,” said Anoop Bhatia, founder and CEO of Nowigence. “This milestone is a key enabler of our mission to become a leading player in a rapidly growing AI market having a minimum potential $20 billion of serviceable market. We thank the entire team at Nowigence for their hard work, as well as our other investors for their support.” Pluaris offers significant differentiation from other contemporary solutions available in the market. “Introduction to Pluaris” provides a video review of the benefits of using key features of the engine. Visit https://www.youtube.com/watch?v=67dK7hpIegc to view the video as a starting point to learn more about Pluaris. To view the full press release, visit https://ibn.fm/cPVxe

Nowigence Inc. (OTCQB: NOWG) is an innovative software-as-a-service (“SaaS”) company focused on developing and bringing to market Pluaris™ — a comprehensive, ready-to-use artificial intelligence (“AI”) platform. Pluaris delivers the combined power of an intelligent reader along with a smart search engine. It works 24/7 reading and analyzing relevant content as is being created in various public and private data sources on topics that one reads either because one enjoys them or because one needs to gather information to fulfill job tasks or other responsibilities.

A personal knowledge management (“PKM”) tool, Pluaris is created for those who want to advance their competitiveness with the power of intelligent reading while searching for information. It accelerates the pace of problem-solving and decision-making. Pluaris is an end-to-end, fully automated, data-science product, offering data-at-scale capabilities mimicking the human process in their abilities to learn. It performs tasks that typically require human intensive activities when reading information from public and private data sources. It provides precise answers to questions asked, analyzes different perspectives, discovers new connections, and creates organized and nested notes. As a result, Pluaris allows teams to work collaboratively from anywhere in the world to share and draw informed conclusions.

Nowigence puts the power of data science into the hands of consumers through integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price. The Pluaris platform generates a trove of critical information to assist individuals, teams, and organizations to quickly build expertise. It reads and analyzes hundreds of pages in a few minutes wherein the data is transformed, linked, taxonomized, and optimized for storage and further trend analysis.

Key Target Market

Pluaris is pre-built with supervised and unsupervised machine learning (ML) and natural language processing (NLP) models. It has three main features. They are:

  • A precise information retrieval engine
  • An intelligent reader, and
  • A Smart Search Engine that intelligently reads and analyzes content written inside files instead of contemporary search tools that use keywords to bring forth URLs or files which users still need to open to read manually.

Pluaris enables distillation of knowledge from hundreds or thousands of sources in seconds rather than the time-consuming method of reading and gaining insight from one source at a time. Keyword-based search-and-retrieval applications do not have the capability to open documents, read content, extract key points, conduct cause-and-effect analysis or answer questions specifically. Pluaris includes those features while going one step further with its semantic capabilities to empower users with interpretations of retrieved information. Nowigence estimates this feature alone can save typical researchers between one and three hours per workday. The platform also extracts only important and relevant information on every monitored or researched topic, reducing “noise” and information overload, a major source of workplace stress.

Pluaris Solution

The Problem

In the modern world, there is a need to consume a tremendous amount of text and transcript-based information for both personal and professional use. This need is met with exceptional challenges due to:

  • Information Overload: For virtually any significant topic, the amount of textual information available and continually generated is vastly more than can be consumed by an individual.
  • Pervasive Distractions: In the era of modern technology, new inputs such as instant messages, e-mails, social media and more reduce attention spans often lead to the disregard of information considered too long and complex to read.
  • Highly Imperfect Human Recall: Information that is read is easily forgotten and, while key insights may be retained, the details are almost certainly lost.
  • Data Sharing/Translation: Working in teams often finds colleagues researching the same content, with much of the information acquired by one individual lost in translation with the communication process to others.

Pluaris

From its early days, Nowigence has worked with pioneers and stalwarts in the fields of machine learning (“ML”) and natural language processing (“NLP”). In doing so, the company was keen to solve the big problem of the information age — too much data exists for it to be processed manually.

Pluaris is designed as a user-friendly platform, requiring no technical expertise or extensive training while avoiding structured or rigid methodology. As a result, Pluaris is adaptable to the unique needs by which individuals absorb knowledge and may be utilized across a variety of different functions and sectors. By leveraging the capabilities of Pluaris’ state-of-the-art no code editing, organizations have the flexibility to improve and tailor results without hiring data scientists. Further, real-time information retrieval, meaning instantaneous delivery of outputs at the click of a button, ensures the client never misses any piece of intelligence.

Pluaris does not simply gather information. The platform was built over the course of three years by a Nowigence team of experts and is designed to understand the context of every sentence it reads. In cases where Pluaris does make an error in contextual interpretation, the user can correct it, instantly giving the correction precedence over the ML’s algorithmic outputs. This removes the biggest criticism against AI/ML platforms, which is that annotating data and developing training datasets to build models takes too much time and effort from internal teams.

Use Cases

There is a virtually unlimited potential for Pluaris to cut through information overload and bring critical data to individuals and enterprises. Nowigence has customized its platform to cater to the needs of a variety of users, including an enterprise customer interested in tracking news and events in the telecom industry. In less than a week, Nowigence was able to quickly create and fine-tune a list of monitored topics, resulting in the team’s access to an annotated and industry specific news feed.

In another instance, Pluaris was useful to an employee of one of the world’s largest aluminum mining companies tasked with preparing talking points for her manager for an upcoming investor meeting. Using the platform, she built a comprehensive database of documents, including notes, transcripts, speeches, question-and-answer sessions, annual reports, and internal documents, some of which were from previous investor meetings. Through the platform’s dashboard and using various filters, she was able to quickly explore that database and pull the information together in a Pluaris Notebook to share directly with her supervisor.

Pluaris has further proven valuable in individual and personal-use cases. For example, a customer who was already using the platform for business intelligence decided to use his account to make improvements in his health after he received a report from his doctor of a high fasting blood sugar level. After uploading a few research reports, reviewing the summaries and exploring the annotated labels, the user set up Pluaris to monitor topics such as “lowering fasting blood sugar” and “low glycemic food.” From those results, he built an action list of daily habits for diet and fitness and, within two months, brought his fasting blood sugar level back down.

Market Considerations

Pluaris users include:

  • Educators, Learners, and Publishers of Interactive Community Knowledge Banks: In a recent report titled “Digital 2022 – Global Overview,” published by the Tribune, it is said that the world between the ages of 16 and 64 spends a daily average of seven hours on the internet. Wikipedia estimates this age group to be 74% of the world’s population of nearly 8 billion people. Pluaris is helping create interactive community knowledge banks for people to save time and improve their quality of learning for specific subjects or topics. The first one being set up is on “healthy living.”
  • Knowledge Workers: Gartner estimates there are more than one billion knowledge workers worldwide as of December 2019. According to a McKinsey report, employees spend 1.8 hours every day searching and gathering information. Nearly all data generated in businesses is in the form of language, but few today have the resources to leverage it. Pluaris, with its basis in data science, synthesizes knowledge from information assisting users to accelerate the pace of problem-solving and decision-making.

Nowigence offers subscription-based pricing to educators, researchers, learners, and publishers of community knowledge banks. Subscription prices are nominal but vary depending upon the volume, variety, velocity, and frequency of accessing large data sets.

Prices vary depending on the scope for small, medium, or large organizations. Typically, the business model is a one-time set up fee to taxonomize and link extracted entities which are user specific jargon. An additional fee is charged for scoping and integrating Pluaris with currently used enterprise tools. Subsequently, a monthly subscription fee is charged.

In 2020, the amount of data in the world was estimated at 44 zettabytes. By 2025, the amount of data generated each day is expected to reach 463 exabytes globally. Reading intelligently while searching for information is going to become an even bigger problem. Nowigence is targeting opportunity across the rapidly growing cognitive computing and personal knowledge management (“PKM”) markets. According to Allied Market Research, the cognitive computing market alone was valued at $8.87 billion in 2018 and is projected to reach a value of $87.39 billion by 2026. This represents a CAGR of 31.6% from 2019 through the end of the forecast period.

Leadership Team

Anoop Bhatia
Founder and Chief Executive Officer

Anoop Bhatia founded Nowigence Inc. and has served as its CEO since 2015. Previously, he worked as a global operation strategic transformation leader for Momentive Performance Material (formerly GE Silicones). Bhatia’s experience includes more than two decades serving in roles for various General Electric companies across different countries, including the U.S., India, The Netherlands and Germany. He played a key role in establishing GE Silicones as the first-ever wholly owned foreign subsidiary established in India in 1996. Bhatia holds a B.S. degree in chemical engineering from BITS in India and completed post-graduate studies in management from Heriot-Watt at Edinburgh in Scotland.

Gordon Haupt
Chief Technology Officer

Gordon Haupt brings more than 20 years of experience building and leading diverse engineering and operations teams, as well as a strong technical background in machine learning, signal processing and statistical data analysis. This includes expertise in speech and text, biotechnology and computer vision applications. He is experienced in all phases of engineering development and operations and is a named inventor on 15 issued patents. Haupt holds a B.S. degree in engineering mechanics from the University of Wisconsin and M.S. and Ph.D. degrees in aeronautics and astronautics from Stanford University.

David Evans
Chief Financial Officer and General Counsel

As an attorney and licensed CPA in the state of New York, David Evans has extensive experience in multistate and international tax policies and guidelines, federal taxation laws, mergers and acquisitions, including valuation of closely held businesses. He is a contributing author to the New York State Tax Service, a six-volume publication of NYS tax laws and regulations. His prior experience includes serving as a managing director for UHY Advisors LLC, a board member and chairperson of the Tax Division Executive Committee of New York State Society of Certified Public Accountants, as well as a past president of the Estate Planning Council of Eastern New York. Evans holds degrees from Hofstra University and State University of New York at Buffalo.

Uday Bawa
Vice President Business Development – India, SEA, and MEA

Uday Bawa brings a wealth of nearly two decades of global P&L experience, growing businesses from scratch in the field of energy and sports. He has worked in B2C and B2B sales environment focusing on product sales, building the brand and generating endorsement deals for renowned sports personalities in India. Previously, he worked in the petrochemicals industry, where he led Houston-based Dorf Ketal’s Fuels business for North America. He was instrumental in generating sponsorship revenues for the Commonwealth Games in Delhi, India, in 2010 from corporate sponsors. He has also managed Indian sports icon Sachin Tendulkar’s commercial interests and endorsement deals. He completed his bachelor’s from Symbiosis International University in India and then his executive MBA from Rice University at Houston in Texas. He is a Doon school (India) alumnus.

Nowigence Inc. (OTCQB: NOWG), closed Wednesday's trading session at $4, even for the day, on 500 volume. The average volume for the last 3 months is 32,990 and the stock's 52-week low/high is $4.00/$4.00.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF).

  • Canada’s federal carbon tax recently hit a record $50/ton, helping fuel a veritable gold rush within the domestic carbon credit industry
  • The move has simultaneously sparked a mass rush amongst Canadian industrial players to transition towards renewable energy sources, with renewable natural gas (“RNG”) top of the list
  • EverGen Infrastructure has become a key player within the Canadian RNG sector, with three active processing plants within British Columbia, and development underway in Alberta and Ontario
  • The company recently acquired a 50% stake in an Ontario-based RNG development, a move which will see the company boost its cumulative production capacity to upwards of 1 million gigajoules per annum

A European energy broker recently reached out to Base Carbon, a Canadian-listed carbon credit-focused investment fund (https://ibn.fm/t3xZW). The motive for the call? The broker was seeking to sell a portfolio of carbon credits generated in 2015 by a Chinese wind farm operation. Canada’s federal carbon tax hit a record $50/ton in April 2022 – effectively penalizing companies on account of their carbon footprint. That in turn has sparked a veritable ‘gold rush’ within the Canadian carbon credit industry, with hordes of companies actively seeking to mitigate their carbon emissions. Simultaneously however, it has also driven home the need for an ever-increasing number of companies to begin adopting renewable natural gas (“RNG”) as a core energy feedstock (https://ibn.fm/Nz6cN). EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), a British-Columbia based renewable natural gas operator, is set to be a key beneficiary of this trend. The ongoing move towards adopting renewable energy sources was best enunciated by Modern Niagara, a Canadian integrated building contractor, which has set a carbon reduction goal of 30% by 2030.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQB: EVGIF), closed Wednesday's trading session at $2.94, even for the day, on volume. The average volume for the last 3 months is 511,702 and the stock's 52-week low/high is $2.12/$4.21.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

Odyssey Health (OTC: ODYY) recently completed a safety evaluation of cohort I of its phase I clinical trial administering PRV-002, the company’s novel drug treatment for concussion. “Findings from the cohort, which included eight healthy human volunteers that received a single dose of PRV-002 or placebo followed by evaluations for abnormal responses, showed that the participants did not exhibit any severe adverse events as PRV-002 was well tolerated,” a recent article reads. “The completion of the safety evaluation is the latest milestone as the company journeys toward providing concussion treatment… With the phase I clinical trial, which consists of 48 healthy subjects, ongoing, Odyssey expects to report additional results as they become available. And while the PRV-002 drug candidate may still be undergoing trials, it is a valuable asset for the company, especially considering recent high-value licensing trends. For instance, biopharmaceutical company AbbVie Inc. (NYSE: ABBV) and clinical-stage biotechnology company Cugene Inc. recently entered into an exclusive worldwide license option agreement for Cugene’s CUG252, a phase 1 drug candidate… Under the terms of the agreement, AbbVie will part with an upfront payment of $48.5 million, with additional payments due later should it exercise the license option. In addition, for another phase 1 drug candidate, AbbVie recently ‘back-loaded the acquisition of privately held Syndesi Therapeutics, paying $130 million initially...’” To view the full article, visit https://ibn.fm/UA6kl

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Wednesday's trading session at $0.21, off by 10.6383%, on 26,675 volume. The average volume for the last 3 months is 5.294M and the stock's 52-week low/high is $0.11/$0.7998.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.